Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016341 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer
A Phase 3 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00016341 is a Phase 3 study that was terminated before completion, run by Gynecologic Oncology Group.
The verdict
NCT00016341, a Phase 3 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Hormone therapy using tamoxifen and megestrol may fight endometrial cancer by blocking the absorption of estrogen. It is not yet known whether chemotherapy is more effective than hormone therapy in treating endometrial cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with that of hormone therapy in treating patients who have recurrent, stage III, or stage IV endometrial cancer.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- DRUG megestrol acetate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016341
The ClinicalTrials.gov registry entry for NCT00016341 describes a study currently listed as terminated, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00016341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00016341 about?
NCT00016341 is a clinical study titled "Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Hormone therapy using tamoxifen and megestrol may fight endometrial cancer by blocking the absorption of estrogen. It is not yet k...
What is the current status of trial NCT00016341?
This trial is currently terminated. It is a Phase 3 study. The study started on 2001-05.
What interventions are being tested in trial NCT00016341?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), megestrol acetate (DRUG).
Who is sponsoring clinical trial NCT00016341?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.